<DOC>
	<DOCNO>NCT01262339</DOCNO>
	<brief_summary>Primary focal hyperhidrosis ( excessive sweating ) debilitate condition affect approximately 3 % population United States . Not major social embarrassment affected individual , also significant negative impact career , school , relationship . Botulinum toxin A ( BTX-A ) , sterile neurotoxin purify Clostridium bacteria , approve U.S. Food &amp; Drug Administration 2004 treatment severe focal axillary hyperhidrosis respond topical antiperspirant . It become promise treatment many patient suffer condition . Over past decade , medication also use effectively many form focal hyperhidrosis hand , foot , forehead , scalp groin . Unfortunately , BTX-A injection primary focal hyperhidrosis palm sol often limit pain post treatment muscle weakness associate procedure . Recent study demonstrate BTX-A deliver across skin via electric current use medical device , call iontophoresis ( FDA 510 ( k ) clearance # K042590 Phoresor IIPM700 ) . Studies limit number patient demonstrate promising result new treatment .</brief_summary>
	<brief_title>BTX-A Treatment Palmar Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Healthy male nonpregnant female Age 16 old If &lt; 18 , parent/legal guardian willing sign consent accompany visit Diagnosis hyperhidrosis disease severity score ( HDSS ) 3 4 Treatment type topical antiperspirant , iontophoresis , systemic anticholinergic fail treat Able come 5 clinical visit study period Diagnosis neuromuscular disease peripheral motor neuropathic disease ( e.g . amyotrophic lateral sclerosis , motor neuropathy ) Diagnosis neuromuscular junctional disorder ( e.g . myasthenia gravis LambertEaton syndrome ) Diagnosis dysphagia Individuals surgical implant pacemaker , orthopedic hardware , etc . Individuals Immunocompromised Systemic infectious illness infection injection site ( ) Known hypersensitivity ingredient formulation drug Organic cause hyperhidrosis Known allergy ingredient general anesthesia Diagnosis cardiac/pulmonary issue disease Women pregnant suspect pregnant</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Primary focal hyperhidrosis</keyword>
	<keyword>interdermal injection</keyword>
	<keyword>iontophoresis</keyword>
	<keyword>BTX-A</keyword>
</DOC>